In addition, the combination of cobimetinib (MEK inhibitor) and an anti-PD-L1 antibody (atezolizumab) is being assessed clinically and has shown promising responses in microsatellite-stable colorectal cancer patients [37]. This evidence concerns the gene MAP2K7 and colorectal cancer.